Citadel Advisors
JUNO

Citadel Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Citadel Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-192,300
Closed -$8.79M – 9175
2017
Q4 		$8.79M Buy
192,300
+128,300
+200% +$6.4M 0.01% 1852
2017
Q3 		$2.87M Buy
64,000
+43,400
+211% +$1.48M ﹤0.01% 2979
2017
Q2 		$616K Sell
20,600
-9,100
-31% -$225K ﹤0.01% 4823
2017
Q1 		$659K Sell
29,700
-18,500
-38% -$397K ﹤0.01% 4602
2016
Q4 		$909K Buy
48,200
+10,900
+29% +$267K ﹤0.01% 3989
2016
Q3 		$1.12M Buy
37,300
+13,900
+59% +$432K ﹤0.01% 3703
2016
Q2 		$899K Buy
23,400
+4,100
+21% +$170K ﹤0.01% 3695
2016
Q1 		$735K Sell
19,300
-1,900
-9% -$66.2K ﹤0.01% 3865
2015
Q4 		$932K Buy
21,200
+4,800
+29% +$238K ﹤0.01% 3671
2015
Q3 		$667K Sell
16,400
-130,200
-89% -$5.71M ﹤0.01% 4385
2015
Q2 		$7.82M Buy
146,600
+122,100
+498% +$6.48M 0.01% 1647
2015
Q1 		$1.49M Buy
+24,500
New +$1.19M ﹤0.01% 3447

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Citadel Advisors's JUNO Position: Q1 2018 in Review

Citadel Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 224,352 shares — an estimated $10.3M sold.

Citadel Advisors first reported a position in JUNO in Q4 2014 and held it in 11 quarters. The position peaked at $19.1M in Q2 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Citadel Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Citadel Advisors sold 224,352 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $10.3M.
  • Citadel Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 11 quarters.
  • Citadel Advisors's Juno Therapeutics, Inc. position peaked at $19.1M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.